ALX Oncology is a clinical-stage immuno-oncology company that aims to fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Their lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is focused on developing a next-generation checkpoint inhibitor that avoids the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.